CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s What Happened

CureVac (NASDAQ:CVAC)’s share price gapped up before the market opened on Friday . The stock had previously closed at $3.40, but opened at $3.68. CureVac shares last traded at $3.71, with a volume of 261,665 shares.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CVAC. UBS Group lowered their price objective on shares of CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday. JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price target on shares of CureVac in a report on Friday, February 14th.

CureVac Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a 50-day moving average price of $3.06 and a 200-day moving average price of $3.20. The firm has a market capitalization of $798.64 million, a PE ratio of 6.47 and a beta of 2.48.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $15.44 million for the quarter, compared to analysts’ expectations of $6.40 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. On average, research analysts expect that CureVac will post 0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CVAC. Greenleaf Trust acquired a new stake in shares of CureVac in the 1st quarter valued at about $31,000. Two Sigma Advisers LP bought a new stake in CureVac in the fourth quarter valued at about $48,000. Jump Financial LLC acquired a new stake in CureVac during the fourth quarter valued at approximately $55,000. D. E. Shaw & Co. Inc. bought a new position in CureVac during the 4th quarter worth approximately $66,000. Finally, Barclays PLC acquired a new position in shares of CureVac in the 3rd quarter worth approximately $67,000. 17.26% of the stock is currently owned by institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.